A Phase 1 Study of AB-1015 Cellular Therapy in People With Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer


Full Title

An Open-Label Phase 1 Study to Evaluate the Safety and Efficacy of Ab-1015 in Patients with Platinum-Resistant Epithelial Ovarian Cancer


Researchers want to find the best dose of AB-1015 to treat ovarian, fallopian tube, and peritoneal cancers. The people in this study have cancer that shrank with cisplatin or carboplatin but now keeps growing even with these drugs.

AB-1015 is a cellular therapy made from your own immune cells called T cells. Some types of cancer can block T cells from attacking cancer cells. If you join this study, we will collect some of your T cells. We will add a gene to help your T cells find and kill cancer cells that make a protein called mesothelin. These genetically modified T cells are called integrated circuit T (ICT) cells, and treatments made from them are ICT therapies.

Before you get AB-1015, you will receive two drugs, fludarabine and cyclophosphamide. These drugs will prepare your body for the treatment. The treatments in this study are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have ovarian, fallopian tube, or peritoneal cancer that keeps growing after at least 2 regimens of treatment.
  • Have cancer that no longer responds to platinum-based therapy.
  • Have completed prior chemotherapy or radiation therapy at least 2 weeks before starting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-608-2091.




Phase I (phase 1)



ClinicalTrials.gov ID